Antares Pharma, Inc. has reported positive results from a multi-centre phase II clinical study evaluating the pharmacokinetic profile of testosterone enanthate administered once-weekly by subcutaneous ...

Antares Pharma, Inc., a leading developer and marketer of parenteral pharmaceuticals, has dosed its first patient in a clinical study evaluating testosterone enanthate administered weekly by ...

EWING, N.J., May 16, 2017 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) announced that data from its Phase 3 study of the pharmacokinetics and safety of subcutaneous testosterone enanthate ...

Xyosted (testosterone enanthate) is a brand-name drug that’s prescribed to treat testosterone deficiency in adults. Xyosted comes as a solution in a prefilled auto-injector pen. It’s typically given ...

Phillips-Medisize, in collaboration with its customer, Ascendis Pharma, was recently recognized with a third industry award for the Skytrofa Auto-Injector. The Red Dot Award recognizes the drug ...

* Antares Pharma Inc - submitted a new drug application (nda) to U.S. Food And Drug Administration (FDA) for quickshot testosterone Sign up here. * Antares Pharma Inc - quickshot testosterone auto ...

The two companies signed an exclusive collaboration agreement for the Aidaptus auto-injector. Owen Mumford, a medical device manufacturer, announced on May 4, 2022 that it has signed an exclusive ...

The auto injector market represents a rapidly expanding segment within the global pharmaceutical delivery systems industry, driven by the increasing prevalence of chronic diseases and the growing ...

Certain health conditions can make it difficult for some men to have normal levels of testosterone. Low testosterone levels, also known as hypogonadism, can affect a person’s life, can cause different ...

The auto-injectors market is forecast to reach a value of USD 5.71 billion in 2025 and is expected to expand to USD 23.31 billion by 2035, growing at a steady compound annualgrowth rate of 8.2% over ...